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Background: Spinal metastatic lesions are a common occurrence among oncology patients 
and contribute to significant morbidity. Treatment options have been limited in their effectiveness 
and scope to this point. 
Objective: This study aims to report the safety and efficacy of radiofrequency ablation (RFA) 
of malignant spinal lesions using a novel RFA bipolar tumor ablation system which includes a 
navigational electrode containing 2 active thermocouples.
 
Study Design: IRB approved multicenter retrospective review of patients receiving RFA as a 
treatment of metastatic osseous lesions between March 2012 and March 2013.
Setting: This study consists of patients from 5 large academic centers. 
Method: One hundred twenty-eight metastatic lesions were identified in 92 patients who 
underwent a total of 96 procedures. Cement augmentation was performed when the vertebral 
body was at risk or had a pathological fracture. Visual analogue scale (VAS) scores were obtained 
preoperatively as well as postoperatively at the one week, one month, and 6 month time points. 
Interval change in the patients’ pain medications was recorded. Postoperative imaging was used 
to assess tumor burden at the treated level when available.
 
Results: RFA was technically successful in all of the lesions without complication or thermal 
injury. Our study demonstrated significant (P < 0.01) decreases in the VAS scores at one 
week, one month, and 6 months postoperatively. In our largest center, 54% of our patients 
experienced a decrease and 30% had no change in their pain medications postoperatively. Sixty-
two percent of the spinal lesions in this largest institution were located in the posterior vertebral 
body. Post-ablation imaging confirmed size of ablation zones consistent with that measured by 
the thermocouples.
Limitations: The main limitations of this study are the heterogeneous patient population, 
data set, and potential confounding variable of concurrent cement augmentation. 
 
Conclusion: The STAR System is an RFA device that was safely and effectively used in the 
treatment of spine metastatic osseous lesions. This new device allows RFA treatment of previously 
untreatable lesions with resultant reduction in pain that was not controlled by systemic or 
radiation therapy.
Key words: Radiofrquency ablation, pain, osseous metastasis, spine, interventional oncology, 
oncology, pain management, tumor, vertebral augmentation
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pain sensitive nerve fibers ceases transmission of pain 
signals. Tumor cell necrosis has also been implicated in 
decreasing the cytokine mediated pain pathways in-
volving interleukins and tumor necrosis factor. RFA also 
delays tumor progression to the sensitive periosteum 
(14,15). The combination of these mechanisms leads 
to rapid decrease in pain that can provide long-lasting 
relief.
The purpose of this multicenter retrospective study 
was to determine the safety and efficacy of RFA using 
an articulating tumor ablation system that permits 
navigation within bone and real time monitoring of the 
peripheral edge of the ablation zone in spinal meta-
static lesions. Additionally, vertebral augmentation was 
delivered via the same guiding cannula if there was al-
ready a pathological fracture, concern for fracture due 




This retrospective analysis involved 5 institutions 
and included patients who received RFA as a treatment 
of osseous metastatic disease using the STAR tumor 
ablation system between March 2012 and March 2013. 
One hundred and twenty-eight osseous spine meta-
static lesions were treated in 92 patients with or with-
out concurrent vertebral augmentation. Two of these 
patients had a second RFA procedure at the same site 
of disease and 2 patients had a second RFA procedure 
for metastasis at a different site leading to a total of 
96 procedures. All patients who underwent RFA with 
the STAR system in these 5 centers were included in the 
study. This retrospective analysis was approved by the 
Institutional Review Board.
The most common type of primary tumor was lung 
cancer (27%), followed by breast cancer (16%), and sar-
coma (9%). Procedural outcomes including complica-
tions and pain relief were examined at each institution. 
All 5 institutions obtained visual analogue scale (VAS) 
scores on patients preoperatively and one month post-
operatively. In addition to these time points, one insti-
tution obtained VAS scores one week postoperatively, 
and one institution obtained scores both one week and 
6 months postoperatively. Table 1 summarizes the VAS 
scores obtained from all 5 centers. 
More detailed data was available from the center 
which performed the largest number of cases, account-
ing for 34 of the 92 patients or 70 of the 128 treated 
Osseous metastatic lesions are common and have been seen in up to 80% of patients with cancer at the time of death (1), with spinal 
metastasis seen in approximately 50% of these patients 
(2). The predilection for growth of tumor cells within 
the bone microenvironment was recognized as far back 
as 1889 by Paget and has been termed the “seed and 
soil” hypothesis (3). While the pathogenesis remains 
unclear, bone metastasis remains the most prevalent 
cause of chronic pain within cancer patients (4). 
The most frequent site of bone metastasis is the 
vertebrae, likely related to the high hematopoietic 
activity and vascularization of the spine (5). Manage-
ment of these patients is challenging and traditionally 
involves a combination of radiation and chemotherapy 
in adjunct with analgesics. Surgery has remained a 
mainstay of treatment in patients with neurologic defi-
cit, instability requiring stabilization, or with a longer 
life expectancy. 
Surgical options in these patients with decreased 
life expectancy are often morbid and present a thera-
peutic dilemma. Minimally invasive procedures, includ-
ing thermal ablation, are safe and effective treatments 
of painful osseous metastatic lesions in patients who 
are not surgical candidates or choose not to undergo 
surgery (6). Radiofrequency ablation (RFA) has been 
well established for the treatment of metastases to the 
liver and kidneys (7-9), and within the past few years has 
been increasingly utilized in management of osseous 
metastases. In the spine, this treatment has tradition-
ally been limited to lesions within the anterior vertebral 
body since this location is more accessible and further 
away from sensitive neural elements (10). Plasma medi-
ated RFA, the most reported method of tumor ablation 
within the spine, employs radiofrequency energy to 
excite electrolytes and create a plasma field that results 
in the disruption of molecular bonds at relatively low 
temperatures (40 to 70 degrees Celsius) (11,12). How-
ever, the resultant thermal profile and ablation zone 
cannot be monitored and are unpredictable, posing a 
potential risk of injury to nearby neural elements.
RFA uses thermal energy to destroy tissue surround-
ing an electrode, resulting in coagulative necrosis of tis-
sue from high temperatures. Optimal tissue destruction 
occurs between 50 – 90°C (13). The radius of the abla-
tion zone is dependent on the tissue temperature and 
time the tissue is maintained at that temperature. Ac-
curate temperature measurements are critical to ensure 
proper tumor kill and also minimize unintended tissue 
destruction. In the short term, thermal destruction of 
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lesions (55%). This institution also included more de-
tailed demographic and procedural data such as lesion 
location, ablation time, number of zones, and ablation 
temperatures, as well as post-procedural imaging when 
available. Table 2 summarizes the VAS scores obtained 
from this center.
Within this larger institution, 13 of the 34 patients 
(38%) were male and 21 (62%) were female. The popu-
lation within this center ranged in age from 35 to 84 
years old, and had a mean age of 60 years. Evidence of 
prior radiation was found in the records of 17 patients 
(43%) and prior chemotherapy in 24 patients (60%) as 
part of their treatment prior to ablation. Of the 70 spine 
lesions, half of these lesions were within the thoracic 
spine, 39% within the lumbar spine, and 11% within 
the sacrum. Additionally, vertebral augmentation was 
performed in 66 of the 70 (94%) spinal lesions to pro-
vide stabilization post-ablation or for pathological frac-
ture. This demographic and augmentation data was not 
available for the other 4 institutions. 
Procedure
Prior to the procedure, written informed consent 
was obtained after a detailed explanation of the 
therapy benefits, treatment alternatives, and complica-
tions. Pre-procedural planning was performed using 
cross-sectional imaging to determine pedicle access and 
the number of targeted ablations based on lesion loca-
tion, size, and pre-clinical thermal distribution curves 
for the device. Magnetic resonance imaging (MRI) was 
preferred due to better evaluation of posterior tumor 
extension and canal or neuroforaminal involvement.
Ninety-four of the procedures were performed 
under conscious sedation. The remaining 2 procedures 
were performed under general anesthesia due to 
intractable pain and inability to achieve pain control 
under conscious sedation. The preferred method of 
treatment is conscious sedation to enable monitoring 
of neurologic symptoms. Fluoroscopy or computed to-
mography (CT) was utilized for image guidance based 
on lesion characteristics and operator preference for 
safety reasons. Full sterile technique was used during 
the procedure including cap, mask, hand hygiene, 
sterile gloves, and sterile drape. RFA was performed 
with the STAR Tumor Ablation System (comprised of 
the SpineSTAR ablation instrument and the MetaSTAR 
generator, DFINE, San Jose, CA). The SpineSTAR is an 
articulating, navigational and bipolar radiofrequency 
electrode containing a pair of thermocouples posi-
tioned along the length of the electrode, 10 and 15 
mm from the center of the ablation zone. There is a 
3:2 length to width aspect ratio ablation zone with 
the maximum ablation zone of 3 cm by 2 cm when the 
proximal thermocouple reaches 50 degrees Celsius. The 
MetaSTAR generator continuously displays the 2 ther-
mocouple readings permitting real time monitoring of 
the peripheral edge of the ablation zone (Fig. 1).
All vertebral lesions were targeted from a trans-
pedicular/parapedicular approach using the provided 
10-gauge co-axial working cannula. The working can-




P Value1 Median Number (n)
Pre-procedural 7.51 2.46 8.00 92
1 week 1.73 2.28 < 0.0001 1.00 56
1 month 2.25 2.44 < 0.0001 1.25 83
6 months 1.75 2.62 0.009 0.00 9
1Based on matched two-tailed Student t test.
Table 2. Visual Analogue Scale (VAS) Scores at our largest institution.
Average Standard Deviation P Value1 Median Number (n)
Pre-procedural 7.35 2.90 8.00 34
1 week 2.47 2.42 < 0.0001 2.00 32
1 month 2.80 2.73 < 0.0001 2.25 29
6 months 1.75 2.62 0.009 0.00 9
1Based on matched two-tailed Student t test.
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nula was advanced into the portion of the vertebral 
body necessary for access to the lesion, and then the ar-
ticulating midline osteotome was used to make desired 
channels prior to ablation. The SpineSTAR electrode 
was then deployed to the desired location. 
A variable number of ablation zones, tempera-
tures, and ablation times were utilized based on size, 
shape, and location of lesion. These variables were 
recorded for each procedure. In cases in which there 
was concern for adjacent neural damage, special neural 
thermal protection techniques, described by Buy et al 
(16), involving epidural or neuroforaminal thermocou-
ples and injection of CO2 or cooled 5% dextrose water 
were used. Following ablation, cement augmentation 
(StabiliT Vertebral Augmentation System, DFINE Inc, 
San Jose, CA) was performed in cases where there was 
a pathologic fracture or vertebral instability was of 
concern due to a large destructive lesion via the same 
working cannula.
Results
RFA was technically successful in all of the 128 osse-
ous metastatic lesions treated without complications or 
thermal injury. The VAS scores obtained from all centers 
as well as our largest center are summarized in Tables 
1 and 2, respectively. The postoperative VAS scores at 
the one week, one month, and 6-month time points 
were statistically significant using a paired two-tailed 
Student t test. 
In the largest center, which comprised 34 of the 
92 treated patients, detailed procedural information 
was obtained. The ablation time at each treated le-
sion ranged from 55 to 653 seconds, with an average 
ablation time of 361 seconds. Each lesion was treated 
with an average of 4.3 overlapping ablation zones. 
The average temperature recorded at the proximal 
thermocouple on the electrode (representing the tem-
perature reading at the most peripheral aspect of the 
ablation zone) was 50 degrees Celsius and the average 
temperature recorded at the distal thermocouple was 
73 degrees Celsius. Twenty-one (62%) of the 34 patients 
had treatment of lesions located in the posterior verte-
bral body (Fig. 2). 
In addition, within this largest institution, change 
in pain medication usage after the ablation was com-
pared to the preoperative information at this institu-
tion. A decrease in pain medications was seen in 54% 
of patients after treatment, with 30% reporting no 
change in medication usage, and 16% saying their pain 
regimen had increased. 
Cement augmentation was successfully performed 
in 92 of the 96 treated lesions through the same work-
ing cannula used for the RFA. Adequate fill was seen in 
all cases. Cement extravasation was noted in 2 patients, 
one into a draining vein and one into a sacral neural 
foramen. Both extravasations were asymptomatic. Two 
of the 4 patients not receiving vertebral augmentation 
went on to fracture and subsequently had cement aug-
mentation at 3 months and one year.
Some patients underwent post-procedural MRI 
which demonstrated discrete ablation zones with a 
length to width aspect ratio of 3:2 consistent in size 
with that expected based on the temperatures ob-
tained by the thermocouplers during the ablation (Fig. 
3). Thirteen of the 34 patients at the largest center had 
follow-up postoperative imaging, 10 of which demon-
Fig. 1. STAR (Spinal Tumor Ablation with Radiofrequency) System Components: A. SpineSTAR Instrument, 10 gauge, 
articulated, extendable bipolar electrode.  B. Distal end of  SpineSTAR containing 2 thermocouples (red dots), located at 10 
and 15 mm from center of  ablation zone which permit real-time monitoring of  proximal peripheral edge of  ablation zone. C. 
MetaSTAR Generator Display: proprietary RF generator with impedance and temperature controlled algorithm.
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Fig. 2. 45-year-old woman with metastatic breast cancer who has multiple metastases including a posterior vertebral body lesion 
at T11.  Axial bone windowed CT image (A) with T11 lytic lesion involving the posterior wall and right pedicle (white arrow). 
Axial T1 weighted (T1W) post contrast MRI image (B) 4 days post-procedure demonstrating the ablation zone (white arrows) 
extending to the posterior vertebral body cortex and into the right pedicle.
A
B
Fig. 3. 52-year-old woman with retroperitoneal leiomyosarcoma metastatic to the posterior L4 vertebral body. 
Prone axial bone windowed CT image (A) demonstrating the STAR device placed from a right pedicle approach during ablation. 
The STAR device is located just anterior to the lytic lesion (*). Axial T1 weighted post contrast MRI image (B) demonstrates 
the ablation zone length being one and a half  times the width, as indicated by the 3 length : 2 width aspect ratio (white arrows) 
obtained with the STAR device.
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strated stable or improved metastatic disease at the 
level of treatment after an average of 92 days. Three 
patients demonstrated progression at the treated level 
after an average of 82 days. Two of these patients un-
derwent a second RFA with the STAR ablation system 
at the same levels. The third patient demonstrated 
diffusely increased metastatic progression after just 16 
days and underwent systemic treatment.
discussion
Bone is the most common site of metastatic disease 
after lung and liver (17) and one of the most common 
causes of chronic pain among cancer patients (18). Ap-
proximately two-thirds of cancer patients will develop 
bone metastases and it is estimated that over 10% of 
patients with cancer will develop symptomatic spinal 
metastases (19). More than 50% of patients with spinal 
metastases have multiple levels involved (20); because 
of this, treating osseous metastatic disease, particularly 
within the spine, is an important aspect of therapy and 
palliation among patients with advanced malignancy 
(21,22). Many patients have a minimal or only brief re-
sponse to traditional therapies and onset of pain relief 
can take months (23). Additionally, invasive surgical 
procedures are usually not warranted in these patient 
populations due to short expected lifespan and co-
morbidities. RFA with or without cement augmentation 
does not hinder or delay the use of adjuvant therapies 
(24). 
The first reported use of RFA in bone was in the 
treatment of osteoid osteoma by Rosenthal et al in 
1992 (25), and since then has been used for treatment 
of osseous metastatic disease (10,26-29). The proce-
dure’s rapid onset of pain relief and low rates of mor-
bidity make it an optimal technique in managing these 
lesions. 
In a multicenter trial of 62 patients, Goetz et al 
noted pain relief in nearly 80% of patients treated with 
RFA (26). Callstrom et al demonstrated RFA to be an 
effective treatment of metastatic pain in approximately 
83% of patients who failed chemoradiation therapy 
(26,27). Thanos et al also found RFA to provide signifi-
cant pain relief in patients who failed standard treat-
ment with pain relief achieved between 4 days and one 
week after therapy in 90% – 100% of patients (27,28). 
In the largest center of this study, 43% of patients were 
documented to have failed radiation while 60% failed 
chemotherapy as their pre-ablation treatment. The 
actual number of patients who failed these treatments 
is likely even higher as there was incomplete documen-
tation of these results within the oncology medical 
records. In all of these referenced cohorts and trials, 
spine lesions were actually a small percentage of the 
total lesions treated. 
The use of RFA in the spine has traditionally been 
limited to the anterior vertebral body due to the close 
proximity of tumor to neural tissues and limited treat-
ment angle derived from the trans- or extra-pedicular 
approach of conventional RFA systems (28). Over half 
of the lesions treated in our largest center were located 
in the posterior vertebral body, lesions that were previ-
ously thought to be untreatable with RFA. Treatment 
of lesions located more posteriorly or with posterior 
cortical bone destruction was contraindicated due to 
the close relationship of the spinal cord and nerve roots 
(29). The posterior wall lesions were easily accessed 
with the SpineSTAR articulating electrode which also 
provided the operator with the additional advantage 
of real time monitoring of the temperature at the pe-
ripheral edge of the ablation zone (Fig. 4).
The addition of cement posteriorly maintains a 
theoretical risk of spinal canal compromise, and should 
be done in experienced hands with caution. The pos-
terior column is the strongest portion of the spine due 
to the large cortical margins and supporting posterior 
elements (30). The decreased necessity of adding ce-
ment to strengthen the column is a benefit. Therefore 
the STAR ablation system has the ability to treat these 
lesions which were previously deemed unsafe.
The ability to create multiple ablation zones 
through the same introducer needle using the naviga-
tional electrode resulted in an average of 4.3 ablation 
zones within each metastatic osseous lesion treated in 
this study allowing for more complete tumor ablation 
(Fig. 4).
In this study, statistically significant pain relief was 
seen among patients at the one week, one month, 
and 6 month post ablation time points. Many studies 
have reported significant and enduring reduction in 
pain control of bony metastasis with improvement in 
overall quality of life after RFA (26-29,31). Long-term 
pain relief has been reported as far out as one year in 
many cases (28,31). Additionally, treatment with RFA 
has been shown to decrease the use of analgesic medi-
cations postoperatively (26-28). Hoffman et al saw this 
decline in 70% of their treated patients (4). A decrease 
in pain medication was seen in 54% of the patients in 
this cohort. 
Ninety-six percent of patients received vertebral 
augmentation following the ablation. Pain relief from 
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Fig. 4. 82-year-old woman with thigh sarcoma metastatic to the posterior L5 vertebral body.  Axial bone windowed CT image (A) 
with destructive right posterior L5 lesion (white arrow). Lateral (B) and frontal (C) fluoroscopic images during RFA with the 
articulated bipolar device within the posterior lesion placed from a right pedicular approach. Axial (D) post-ablation T1 image 





cementoplasty has been reported in the literature to 
range from 47% to 87% (32). Prior destruction of tu-
mor with RFA has been linked to a more complete fill 
with cement providing additional structural support 
(12,33,34). A synergistic response between RFA and 
cementoplasty has been reported which can provide 
pain relief for an average of 7.3 months (35). The com-
bination of cement augmentation following RFA using 
the STAR tumor ablation system was shown to be both 
safe and efficient, allowing the patient to undergo 
both treatments using the same working cannula and 
decreasing the total sedation and procedural time. 
There are several limitations to this retrospective 
study. While a prospective study design is preferred, 
observational studies are the mainstay for initial pro-
cedure reports.
Pain Physician: July/August 2014; 17:317-327
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The breadth of demographic and treatment data 
provided by each treatment center varied widely. De-
tailed data was obtained in the center which treated 
the most patients, but not available from the other 
4 centers. While the calculated P-values were statisti-
cally significant within the 70 lesions treated by this 
one center, providing some support for the ability to 
generalize the data from this center, a more cohesive 
data set from all centers would have been beneficial. 
Data collected from each center was heterogeneous. 
Six month postoperative VAS scores were only recorded 
at one institution, and could only be obtained in 9 pa-
tients due to patient death from metastatic disease or 
loss to follow-up. By the same regard, VAS scores were 
not obtained at every time point for each patient even 
within the same institution. 
Additionally, the patient population was very hetero-
geneous with a variety of primary tumor types and degree 
of metastatic involvement. Due to the innate severity of 
metastatic disease, many patients had only a few months 
to live allowing for a wide range of follow-up data. 
The majority of the ablations were followed by 
cement augmentation which confounds the post-
procedural pain evaluation as to the contributing 
factor of pain reduction. Most lesions had pathologic 
fractures or were at risk of fracture and vertebral 
augmentation was used for stabilization. It has well 
been accepted that vertebral augmentation is a ther-
apeutic option for pain palliation and stabilization of 
pathologic fractures of the spine (36). However, with 
vertebral augmentation alone and especially in those 
who have failed or exhausted radiation therapy, 
there can be progression of disease in the poste-
rior vertebral body where cement is typically absent 
with subsequent posterior wall destruction and ca-
nal extension (Fig. 5). In this series of patients with 
posterior wall involvement and posterior RFA, there 
were cases where posterior wall extension was halted 
following RFA while spinal tumors in other vertebra 
progressed during continued systemic therapy (Fig. 
6). In the cases (n = 2) in which tumor progression was 
observed, the STAR procedure permitted additional 
Fig. 5. 32-year-old woman with metastatic colon cancer 
who has back pain centered at metastatic lesions at T8 
and T9 previously treated with radiation therapy. 
Sagittal T1 weighted inversion recovery MRI image 
(A) with anterior metastatic lesion and pathologic 
superior endplate fracture of  T8 (white arrow). 
Metastatic lesion at T9 is not shown. Lateral 
fluoroscopic image (B) during vertebral augmentation 
of  T8 and T9 with visualized pathologic superior 
endplate fracture of  T8 (white arrow). Sagittal T1 
weighted fat suppressed post contrast MRI image (C) 
5 months following vertebral augmentation (white 
asterisks) without ablation demonstrating new tumor in 
the posterior vertebral bodies with central canal extension 
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Fig. 6. 55-year-old woman who has metastatic renal cell cancer with back pain centered at metastatic lesions and pathologic 
fractures of  L2 and L3 treated previously with radiation therapy. 
Sagittal T1 weighted post contrast MRI image (A) demonstrating large enhancing lesions at L2 and L3 and smaller enhancing 
lesions at T11 and T12 prior to ablation. L1 and L5 are labeled for counting purposes. Sagittal T1 weighted post contrast MRI 
image (B) 6 months post L2 and L3 ablation with cement augmentation demonstrating a lack of  tumor progression within 
the treated levels, including posteriorly where no cement was administered (white asterisks), while the adjacent T11 and T12 
non-ablated lesions (white arrows) markedly increased in size while on systemic therapy. Axial T2 weighted MRI image (C) 
demonstrates progression of  the T11 tumor into the spinal canal. 
Pain Physician: July/August 2014; 17:317-327
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